Monopar Therapeutics presented baseline data from its Phase 3 FoCus trial showing significant residual disease burden in Wilson disease patients, including high rates of cirrhosis, neurologic, and psychiatric symptoms despite treatment. The company also shared long-term safety data for its investigational therapy ALXN1840, demonstrating neutral molybdenum balance and no toxicity over six years. These findings highlight ongoing challenges in managing Wilson disease and support ALXN1840's safety and efficacy profile. The data were presented at the AASLD Liver Meeting 2026, providing valuable insights for clinicians and advancing treatment options.
Monopar's data on Wilson disease treatment and ALXN1840 safety is the subject here. For readers following the health sector, of 150 priced US health stocks tradable on Pluang, 121 rose and 18 fell today. Notable movers include NUWE at USD 4.72 (+3.06%), CTXR at USD 0.54 (-2.98%), and LQDA at USD 45.67 (+2.86%). This snapshot is as of Nov 09, 2026 19:41 WIB.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
